HACKENSACK, N.J. and PETACH TIKVAH, Israel, May 1, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its Phase 2 clinical study of NurOwn in amyotrophic lateral sclerosis (ALS) at the International Society for Cellular Therapy (ISCT) annual conference in London, England, and the World Advanced Therapy and Regenerative Medicine Congress in London, England.

International Society for Cellular Therapy Annual Conference

Date:

Thursday, May 4

Time:

3:30pm - 5:00pm CET

Location:

ExCeL London, London, England

Title:

Safety and Efficacy of Transplantation of NurOwn (Autologous Mesenchymal Stromal Cells Secreting Neurotrophic Factors) in Patients with ALS: a Phase 2 Randomized Double Blind Placebo Controlled Trial

Presenter:

Dr. Yael Gothelf, Chief Regulatory and Scientific Officer, BrainStorm Cell Therapeutics

Date:

Thursday, May 4

Time:

5:00pm - 6.30pm CET

Location:

ExCeL London, London, England

Title:

Poster presentation titled: In vivo modulation of neurotrophic and inflammatory factors in the CSF of ALS patients treated with NurOwn (MSC NTF cells)

Presenter:

Dr. Yael Gothelf, Chief Regulatory and Scientific Officer, BrainStorm Cell Therapeutics

World Advanced Therapies & Regenerative Medicine Congress 2017

Date:

Thursday, May 18

Time:

2:40pm CET

Location:

Business Design Centre, London

Title:

Brainstorm's NurOwn Treatment for Neurodegenerative Diseases

Presenter:

Chaim Lebovits, Chief Executive Officer, BrainStorm Cell Therapeutics

About the International Society for Cellular TherapyEstablished in 1992, the International Society for Cellular Therapy (ISCT) is a global society of clinicians, researchers, regulators, technologists and industry partners with a shared vision to translate cellular therapy into safe and effective therapies to improve patients' lives worldwide. ISCT is the global leader focused on pre-clinical and translational aspects of developing cell-based therapeutics, thereby advancing scientific research into innovative treatments for patients. ISCT offers a unique collaborative environment that addresses three key areas of translation: Academia, Regulatory and Commercialization. Through strong relationships with global regulatory agencies, academic institutions and industry partners, ISCT drives the advancement of research into standard of care. Comprised of over 1300 cell therapy experts across five geographic regions and representation from over 50 countries, ISCT members are part of a global community of peers, thought leaders and organizations invested in cell therapy translation. For more information about the society, key initiatives and upcoming meetings, please visit: http://www.celltherapysociety.org.

About the World Advanced Therapies & Regenerative Medicine Congress12 years ago when the World Stem Cells Congress was launched, the stem cells sector was one of scientific interest. Focusing on the challenges of how to transform these little precursor cells eventually into new tissues and organs. The first stem cells conference was relatively small with only 80 people attending the first event, but we knew we were on the verge of something huge and exciting. In May 2017 the newly named World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From process development to clinical translation this congress will bring you the most exciting case studies and new data. Experts in every area will help you tackle the process and regulatory hurdles of developing these new therapeutic formats all the way through manufacture and into the clinic.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult mesenchymal stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to approximately 75 patients with ALS in clinical trials conducted in the United States and Israel. In a randomized, double-blind, placebo-controlled clinical trial conducted in the U. S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. For more information, visit the company's website at http://www.brainstorm-cell.com.

Read More

Safe-Harbor StatementStatements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Media:Uri Yablonka Brainstorm Cell Therapeutics Inc. Phone: (646) 666-3188 uri@brainstorm-cell.com

Investors:Michael Rice LifeSci Advisors, LLC Phone: 646-597-6979 mrice@lifesciadvisors.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-two-scientific-conferences-in-may-300448600.html

Continue reading here:
BrainStorm to Present at Two Scientific Conferences in May - Yahoo Finance

Comments are closed.